SR One Capital Management, LP
CIK
1910264
Location
Redwood City, CA
Portfolio Value
Mid
$1,039,007,697
Diversification
Diversified
Filing Date
Global Rank
#2,456
/ 8,795
▲ 379
· as of Jun 2026
Top Industry
Biotechnology
97.4%
3Y Alpha vs SPY
+14.8%
Period ended 3 months ago
Filed Aug 12, 2026 · 56d
19 quarters · since Dec 2021
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
15 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
28.4%
+4.9 pts
Top 5
71.0%
−2.5 pts
Top 10
95.1%
−2.6 pts
HHI
1,399
Diversified+58
Portfolio Trend
19 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $1,039,007,697 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| ORIC | Oric Pharmaceuticals, Inc. | +100,455 | 4,615,384 | $49,984,608 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reducedNo qualifying positions this quarter.
Sold Out
Positions the filer fully exited
2 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | 430,330 | $21,107,686 | |
| — | 2,346,630 | $0 | ||
| No positions match the current search. | ||||
15 tracked positions ·
$1,039,007,697 total
· filing declares
15 positions · $1,039,007,705
· as of Jun 30, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| MANE |
Veradermics, Inc
Healthcare
|
Held | 2,401,868 | $295,285,651 | 28.42% | |
| ZBIO |
Zenas BioPharma, Inc.
Healthcare
|
Held | 5,037,854 | $127,860,734 | 12.31% | |
| CRSP |
CRISPR Therapeutics AG
Healthcare
|
Held | 2,038,763 | $111,194,134 | 10.70% | |
| AVLN |
Avalyn Pharma Inc.
Healthcare
|
NEW | 3,308,649 | $108,920,725 | 10.48% | |
| DSGN |
Design Therapeutics, Inc.
Healthcare
|
Held | 6,526,476 | $94,438,107 | 9.09% | |
| ODTX |
Odyssey Therapeutics, Inc.
Healthcare
|
NEW | 3,794,883 | $71,002,260 | 6.83% | |
| ALMS |
Alumis Inc.
Healthcare
|
Held | 1,959,896 | $55,151,473 | 5.31% | |
| ORIC |
Oric Pharmaceuticals, Inc.
Healthcare
|
Added | 4,615,384 | $49,984,608 | 4.81% | |
| MLYS |
Mineralys Therapeutics, Inc.
Healthcare
|
Held | 1,563,966 | $42,195,802 | 4.06% | |
| SPRY |
ARS Pharmaceuticals, Inc.
Healthcare
|
Held | 4,012,903 | $32,143,353 | 3.09% | |
| MOBI |
Mobia Medical, Inc.
Healthcare
|
NEW | 1,986,072 | $26,613,364 | 2.56% | |
| NKTX |
Nkarta, Inc.
Healthcare
|
Held | 3,333,333 | $9,433,332 | 0.91% | |
| OCS |
Oculis Holding AG
Healthcare
|
Held | 641,022 | $8,890,975 | 0.86% | |
| RARE |
Ultragenyx Pharmaceutical Inc.
Healthcare
|
Held | 137,753 | $4,599,572 | 0.44% | |
| ENGN |
enGene Therapeutics Inc.
Healthcare
|
Held | 747,750 | $1,293,607 | 0.12% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.